Compare SKYT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | AUPH |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 1999 |
| Metric | SKYT | AUPH |
|---|---|---|
| Price | $29.26 | $14.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $26.50 | $17.25 |
| AVG Volume (30 Days) | ★ 3.2M | 836.9K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | 0.55 |
| Revenue | ★ $346,587,000.00 | $265,808,000.00 |
| Revenue This Year | $28.48 | $21.76 |
| Revenue Next Year | $41.29 | $16.45 |
| P/E Ratio | ★ $11.17 | $25.87 |
| Revenue Growth | 0.19 | ★ 20.62 |
| 52 Week Low | $5.67 | $6.55 |
| 52 Week High | $36.27 | $16.54 |
| Indicator | SKYT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 38.73 |
| Support Level | $28.13 | $14.21 |
| Resistance Level | $30.87 | $14.66 |
| Average True Range (ATR) | 1.62 | 0.45 |
| MACD | -0.80 | -0.02 |
| Stochastic Oscillator | 21.80 | 3.88 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.